Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.58 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | MAP3K7 | O43318 | 3/20 | 0.34 |
| ▸ | TAB1 | Q15750 | 3/20 | 0.34 |
| ▸ | AKT1 | P31749 | 3/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | STK4 | Q13043 | 4/20 | 0.32 |
| ▸ | STK3 | Q13188 | 4/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4780230 | 0.84 | CHEK1 (0.56) | CHEK1NOTUMAURKAMAP3K7TAB1 | |
| SCHEMBL3236479 | 0.84 | CHEK1 (0.56) | CHEK1NOTUMAURKAMAP3K7TAB1 | |
| SCHEMBL2783376 | 0.81 | CHEK1 (0.53) | CHEK1NOTUMAURKAMAP3K7TAB1 | |
| SCHEMBL16765827 | 0.80 | CHEK1 (0.51) | CHEK1NOTUMMAP3K7TAB1LRRK2 | |
| SCHEMBL21678540 | 0.78 | CHEK1 (0.50) | CHEK1NOTUMAURKAAKT1IRAK4 | |
| SCHEMBL20195284 | 0.77 | CHEK1 (0.49) | CHEK1NOTUMAURKAMAP3K7TAB1 | |
| SCHEMBL4268054 | 0.77 | MET (0.50) | CHEK1AURKAMAP3K7TAB1AKT1 | |
| SCHEMBL16765811 | 0.77 | CHEK1 (0.49) | CHEK1NOTUMAURKATRPA1IRAK4 | |
| SCHEMBL12065776 | 0.77 | CHEK1 (0.49) | CHEK1NOTUMAURKAMAP3K7TAB1 | |
| SCHEMBL16765141 | 0.77 | CHEK1 (0.49) | CHEK1NOTUMAURKAMAP3K7TAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220112214-A1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112214-A1 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, FRK | CHEK1 868/4885NOTUM 4783/4885AURKA 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.